← Leaderboards
Daniel R Wahl
University Of Michigan At Ann Arbor
$6,515,358
Attributed
$8,402,850
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,402,850 · 5
By mechanism
R01$3,774,985 · 2
R37$2,760,954 · 1
K08$1,143,094 · 1
P50$723,817 · 1
Top collaborators
- Alexander H. Stegh2 shared
- Deepak Nagrath1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Xing Fan$5,437,064
- Maria G Castro$22,126,725
- Meredith A Morgan$5,182,920
- Theodore S Lawrence$30,022,406
- James J. Moon$14,172,333
Others in their field
Other Emerging Leaders on “Metabolic”
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Barbara Halina Braffett · George Washington University$22,016,904
- Ionut Bebu · George Washington University$18,816,779
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$15,459,738
- Rainer Lohmann · University Of Rhode Island$14,400,221
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$14,236,023
Research focus
MetabolicGlioblastomaPurinesIn VivoRadiationTracerRadioresistantRadiation Dose UnitRadiation ResistanceFda ApprovedDna RepairPrimary Brain NeoplasmsRadiation ResponseInhibitorPatient Derived Xenograft ModelPathway InteractionsSignal TransductionTumorCellsBrainMediatingMass Spectrum AnalysisNucleotide MetabolismPharmaceutical Preparations
Grant awards (16)
New methods to measure and interrupt metabolic fluxes in brain cancer$2,820,337
R01 · FY2025 · CA · contact PI
Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma$561,344
R37 · FY2025 · CA · contact PI
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.$480,412
R01 · FY2025 · NS
Project 2: Overcoming GBM RT-resistance$240,081
P50 · FY2025 · CA · contact PI
Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma$533,277
R37 · FY2024 · CA · contact PI
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.$474,236
R01 · FY2024 · NS
Project 2: Overcoming GBM RT-resistance$230,479
P50 · FY2024 · CA · contact PI
Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma$550,119
R37 · FY2023 · CA · contact PI
Project 2: Overcoming GBM RT-resistance$253,257
P50 · FY2023 · CA · contact PI
De Novo Nucleotide Synthesis as a Mediator of Radiation Resistance and a Therapeutic Target in Glioblastoma$187,987
K08 · FY2023 · CA · contact PI
Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma$561,344
R37 · FY2022 · CA · contact PI
De Novo Nucleotide Synthesis as a Mediator of Radiation Resistance and a Therapeutic Target in Glioblastoma$187,907
K08 · FY2022 · CA · contact PI
Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma$554,870
R37 · FY2021 · CA · contact PI
De Novo Nucleotide Synthesis as a Mediator of Radiation Resistance and a Therapeutic Target in Glioblastoma$255,400
K08 · FY2021 · CA · contact PI
De Novo Nucleotide Synthesis as a Mediator of Radiation Resistance and a Therapeutic Target in Glioblastoma$255,400
K08 · FY2020 · CA · contact PI
De Novo Nucleotide Synthesis as a Mediator of Radiation Resistance and a Therapeutic Target in Glioblastoma$256,400
K08 · FY2019 · CA · contact PI